Corbus Pharmaceuticals Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $86.56M
- P/E (TTM)
- –
- Dividend yield
- –
About Corbus Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Corbus Pharmaceuticals Holdings is a clinical-stage biopharmaceutical firm that develops treatments for oncology and metabolic conditions. Its pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4 to treat solid tumors such as cervical, urothelial, and head and neck cancers. It also develops CRB-913, an oral cannabinoid receptor inverse agonist for obesity management. Because its programs remain in clinical testing, Corbus has no commercial products or commercial customers; its development efforts target patients suffering from advanced solid cancers and obesity.
The text does not state the location of the company's headquarters. Corbus conducts clinical trials in the United States and Europe, with partner studies active in China. The company holds licensing rights across the United States, Canada, Europe, the United Kingdom, and Australia for its lead cancer drug, alongside global rights for its obesity candidate. Corbus does not own manufacturing facilities, instead utilizing third-party contract manufacturers and partner agreements to supply compounds for its research programs.
Summary of the business section of Corbus Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Corbus Pharmaceuticals Holdings, Inc.
- Founded
- 2009
- Headquarters
- Norwood, MA
- Address
- 500 River Ridge Drive 02062
- Phone
- (617) 963-0103
- Website
- corbuspharma.com
- Employees
- 36, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- EISNERAMPER LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- CRBP
- Exchange
- Nasdaq
- IPO date
- Oct 27, 2014
- Shares outstanding
- 19M, Aug 4, 2026
- Public float
- $67.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-30 reverse, Mar 7, 2023; 1-for-30 reverse, Feb 14, 2023
- SEC CIK
- 1595097
- CUSIP
- 21833P301
- ISIN
- US21833P3010
- LEI
- 529900MX6XCNZC7MM155
- EIN
- 46-4348039
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yuval Cohen | Chief Executive Officer, Director | 157,316 |
| Leonardo Viana Nicacio | Chief Medical Officer | 58,333 |
| Nishant C. Saxena | Chief Business Officer | 77,900 |
| Sean F. Moran | Chief Financial Officer | 84,694 |
| Dominic Smethurst | Chief Medical Officer | 89,790 |
| Ian Hodgson | Chief Operating Officer | 51,080 |
| Yong Ben | Director | 9,383 |
| John Kenneth Jenkins | Director | 3,833 |
| Anne Altmeyer | Director | 7,579 |
| Winston Kung | Director | 12,140 |
| Brent Pfeiffenberger | Director | 7,500 |
| Rachelle Suzanne Jacques | Director | 11,383 |
| Alan F. Holmer | Director | 10,629 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Cohen | $3.75M | $2.59M | $1.79M | $244 | – |
| FY2024 Dr. Cohen | $4.25M | $4.07M | $2.66M | $354 | – |
| FY2023 Dr. Cohen | $1.14M | $1.36M | $778.56K | $181 | – |
| FY2022 Dr. Cohen | $1.44M | $406.59K | $771.21K | $9 | – |
| FY2021 Dr. Cohen | $4.86M | $1.40M | $930.36K | $49 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We had 36 full-time employees at December 31, 2025.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 9, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 13, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 6, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 7, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 3, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 14, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jan 10, 2014 | Name change | Name changed from SAV Acquisition Corp to Corbus Pharmaceuticals Holdings, Inc. |